(CercleFinance.com) – Theradiag said on Monday that it was targeting profitability for early 2023, an announcement which was greeted by a gain of nearly 10% in its share price on Euronext Paris.
The company specializing in in vitro diagnostics reported in the morning an operating loss of 129,000 euros in the first half, against -178,000 euros a year earlier, an improvement of 28%.
Its net loss, at 56,000 euros, is now almost at equilibrium and represents only 0.9% of turnover, argues the company.
On the strength of its reorientation initiated several semesters, Theradiag now says it wants to continue the execution of its strategic plan in the
prospect of reaching a structural positive margin, at the latest in early 2023.
The group, which claims to have “tremendous potential” for development given the size of the biotherapy monitoring market, says it has achieved a turnover of 6.3 million euros in the first six months of the year. year, compared to 5.5 million in the first half of 2021, an increase of 14%.
At the end of the morning, the Theradiag title climbed 9.6% in substantial volumes, already seven times higher than the average of the last four stock market sessions.